Octreotide Subcutaneous Depot Study in Acromegaly Now Recruiting

A trial update dated September 25, 2026 lists a new observational study of octreotide subcutaneous depot in patients with acromegaly. The study, registered as NCT07583563, is currently listed with a status of recruiting. No phase designation is included in the available record. The listing identifies the study as observational, meaning it is designed to gather data on patients rather than test an intervention against a comparator. No results have been posted for this study at this time. The available record does not include enrollment numbers, study duration, or specific endpoints being measured. Octreotide is an approved compound, and this study focuses specifically on its subcutaneous depot formulation in the context of acromegaly, a condition in which the drug is used. Readers should note that a recruiting status indicates the study is open to enrollment and has not yet reported findings. As with any observational study, conclusions about outcomes cannot be drawn until data collection is complete and results are published. Updates to the trial status, including changes in recruitment or eventual completion, may be reported separately as they become available through the official registry listing. For more background on this compound, readers can consult the compound overview.